Court Ruling Limits Ozempic Copies in Favor of FDA, Novo Nordisk

A Texas judge denied a motion from compounders to keep making versions of Ozempic and Wegovy, clearing the way for FDA enforcement and other lawsuits.

The injectable drug Ozempic in Houston on July 1, 2023. David J. Phillip/AP Photo

A federal court in Texas has ruled against a trade group representing compounding pharmacies, siding with the Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk in a dispute over copies of the popular weight-loss and diabetes drugs Ozempic and Wegovy.

The ruling, issued April 24 in the U.S. District Court for the Northern District of Texas, denied a request from the Outsourcing Facilities Association (OFA) to block the FDA’s recent decision to remove semaglutide from its drug shortage list.